ASH 2025 Spotlight: Transformative Sickle Cell Disease Clinical Developments
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared on LinkedIn:
”A day filled with remarkable science in clinical development for Sickle Cell Disease at the American Society of Hematology 2025 national meeting.
Using novel new ways to positively affect the Erythron, three new approaches were discussed :
1. Transcriptome guided novel target by affecting NEDDylation through DCN1 pathway, thereby augmenting fetal hemoglobin rise, predicted to raise fetal hemoglobin close to gene therapy ranges by just an oral drug delivery platform.
2. Knockdown of G-CSF in Sickle Cell Disease, hoping it will impact Netosis and vaso occlusion. Thromboinflammation front and center. Very complimentary to our work being done by the Sickle Cell Hemostasis Taskforce.
3. Acute chest syndrome: acute treatment by reduction of NETs
Additionally proud to have shared our clinical work on standardizing point of care testing with near 100% concordance with HPLC for all hemoglobinopathies in the USA for the first time.”
Stay updated with Hemostasis Today.
-
Jan 31, 2026, 16:35IV Thrombolysis Does Not Improve Vision in Acute CRAO: Ahmed Koriesh on TenCRAOS Study
-
Jan 31, 2026, 16:24Joyce John Chalakkal: The Dangerous Area of The Face….
-
Jan 31, 2026, 16:04Rayya Saadiq Reflects On Qatar Health Congress 2026
-
Jan 31, 2026, 15:12Amar Raval on Oral Thin Film Drug Delivery Systems for Thrombosis Therapy
-
Jan 31, 2026, 14:40Heghine Khachatryan on WFH’s Call to Advance Health Equity for People with Bleeding Disorders
-
Jan 31, 2026, 14:10Emilia Arturo: Snake Venom, Clotting, and CryoEM!
-
Jan 31, 2026, 08:13Ming Y Lim On The Value of National Mentorship
-
Jan 31, 2026, 06:37Christian Schulze Presents The Post-Hoc Analysis of the DanGer Shock Trial
-
Jan 31, 2026, 06:27Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial